Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement

Shattuck Labs, Inc.

2025-Q2 EPS reported -$0.51

Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.
Cash $50.5M as of June 30; up to $103M from oversubscribed private placement led by OrbiMed to fund ops into 2029.
Submitted IND for SL-325 (DR3 blocking antibody) in July 2025; clearance expected Q3 2025; first dosing in Phase 1 expected Q3 2025.
Phase 1 trial in healthy volunteers to complete Q2 2026; funds expected to support operations into 2029.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.